Biosimilars Market Forecast 2022–2028: Strong Growth to US$ 136.07 Billion at 34.8% CAGR

 Biosimilars provide cost-effective alternatives to branded biologic therapies used in treating conditions such as cancer, autoimmune disorders, and chronic diseases. Their adoption is helping improve treatment accessibility across global healthcare systems.

Biosimilars Market Overview

The biosimilars market is witnessing strong expansion due to the rising prevalence of chronic and autoimmune diseases and the increasing need for affordable biologic therapies. Biosimilars are biological medicines that are highly similar to already approved reference biologics and meet the same standards of quality, safety, and efficacy. These therapies play a crucial role in improving patient access to life saving treatments while reducing healthcare expenditure. The global biosimilars market was valued at US$ 18.44 billion in 2021 and is projected to reach US$ 136.07 billion by 2028, registering a robust CAGR of 34.8% during the forecast period.

Market Drivers and Growth Factors

One of the primary drivers of the biosimilars market is the increasing burden of chronic diseases such as cancer, diabetes, and autoimmune disorders. Conditions like rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, and psoriasis are becoming more prevalent worldwide, creating sustained demand for long term biologic therapies. The high cost of originator biologics has intensified the need for cost effective alternatives, positioning biosimilars as a preferred option for patients and healthcare providers.

Another major growth driver is the rising number of regulatory approvals. Regulatory agencies such as the US Food and Drug Administration and the European Medicines Agency have established clear pathways for biosimilar approvals, which has accelerated product launches across multiple therapeutic areas. Increasing awareness among physicians and patients regarding the safety and efficacy of biosimilars further supports market adoption.

Strategic initiatives by key market players also contribute significantly to market growth. Companies are actively engaging in mergers, acquisitions, partnerships, and global expansion strategies to strengthen their product portfolios and geographic reach.

Download Free Sample PDF- https://www.theinsightpartners.com/sample/TIPHE100001246 

Segmental Analysis

Based on disease indication, the biosimilars market is segmented into cancer,diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share due to the high demand for oncology biologics and rising cancer incidence globally. The autoimmune disease segment is expected to register the fastest growth rate, supported by increasing diagnosis rates and long term treatment requirements.

By drug class, the market includes granulocyte colony stimulating factors, insulin, TNF blockers, monoclonal antibodies, and others. Granulocyte colony stimulating factors dominated the market in 2021 due to their widespread use in cancer supportive care. Monoclonal antibodies and TNF blockers are expected to experience rapid growth owing to their application in autoimmune and inflammatory diseases.

In terms of route of administration, intravenous biosimilars accounted for the largest share, driven by their use in hospital based treatments. Subcutaneous administration is gaining traction due to patient convenience and increasing homecare adoption. Hospitals remain the leading end users, while the homecare segment is projected to grow at the highest CAGR.

Regional Insights

North America represents a major share of the global biosimilars market, supported by strong regulatory frameworks, high biologics usage, and increasing healthcare cost pressures. The United States leads the region due to a growing number of FDA approved biosimilars and expanding clinical adoption. Europe follows closely, driven by early biosimilar acceptance and favorable reimbursement policies. The Asia Pacific region is expected to witness rapid growth due to increasing healthcare investments, expanding patient populations, and rising awareness of biosimilar therapies.

Key Players in the Biosimilars Market

Major companies operating in the biosimilars market include:

• Amgen Inc

• Celltrion Inc

• Sanofi SA

• Biocon Ltd

• Pfizer Inc

• Samsung Bioepis Co Ltd

• Coherus BioSciences Inc

• Eli Lilly and Company

• Sandoz AG

• Teva Pharmaceutical Industries Ltd

• Dr. Reddy’s Laboratories Ltd

These players focus on product innovation, regulatory approvals, and global partnerships to maintain competitive advantage.

Future Outlook

The future of the biosimilars market remains highly promising as healthcare systems continue to prioritize cost containment and patient access to advanced therapies. Ongoing patent expirations of blockbuster biologics will create significant opportunities for biosimilar manufacturers. Continued regulatory support, technological advancements in biologics manufacturing, and increasing physician confidence are expected to further accelerate market growth. As competition intensifies, pricing benefits and expanded treatment accessibility will strengthen the role of biosimilars in global healthcare delivery.